Free Trial
NASDAQ:ZYXI

Zynex (ZYXI) Stock Price, News & Analysis

Zynex logo
$2.41 -0.11 (-4.37%)
Closing price 04:00 PM Eastern
Extended Trading
$2.49 +0.08 (+3.32%)
As of 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Zynex Stock (NASDAQ:ZYXI)

Key Stats

Today's Range
$2.37
$2.57
50-Day Range
$2.11
$7.66
52-Week Range
$1.93
$12.19
Volume
158,812 shs
Average Volume
151,440 shs
Market Capitalization
$72.85 million
P/E Ratio
16.07
Dividend Yield
N/A
Price Target
$10.25
Consensus Rating
Hold

Company Overview

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Zynex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

ZYXI MarketRank™: 

Zynex scored higher than 61% of companies evaluated by MarketBeat, and ranked 289th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zynex has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Zynex has only been the subject of 3 research reports in the past 90 days.

  • Read more about Zynex's stock forecast and price target.
  • Earnings Growth

    Earnings for Zynex are expected to grow by 135.00% in the coming year, from $0.20 to $0.47 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zynex is 15.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.68.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zynex is 15.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.26.

  • Price to Book Value per Share Ratio

    Zynex has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Zynex's valuation and earnings.
  • Percentage of Shares Shorted

    21.28% of the float of Zynex has been sold short.
  • Short Interest Ratio / Days to Cover

    Zynex has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Zynex has recently decreased by 1.31%, indicating that investor sentiment is improving.
  • Dividend Yield

    Zynex does not currently pay a dividend.

  • Dividend Growth

    Zynex does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    21.28% of the float of Zynex has been sold short.
  • Short Interest Ratio / Days to Cover

    Zynex has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Zynex has recently decreased by 1.31%, indicating that investor sentiment is improving.
  • News Sentiment

    Zynex has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 33 news articles for Zynex this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Zynex to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zynex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $148,300.00 in company stock.

  • Percentage Held by Insiders

    49.28% of the stock of Zynex is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 29.68% of the stock of Zynex is held by institutions.

  • Read more about Zynex's insider trading history.
Receive ZYXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter.

ZYXI Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

ZYXI Stock Analysis - Frequently Asked Questions

Zynex's stock was trading at $8.01 at the beginning of 2025. Since then, ZYXI stock has decreased by 70.1% and is now trading at $2.3940.
View the best growth stocks for 2025 here
.

Zynex, Inc. (NASDAQ:ZYXI) released its quarterly earnings results on Tuesday, March, 11th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.11. The business had revenue of $45.98 million for the quarter, compared to analyst estimates of $53.65 million. Zynex had a trailing twelve-month return on equity of 13.05% and a net margin of 2.49%.
Read the conference call transcript
.

Top institutional investors of Zynex include Janney Montgomery Scott LLC (0.49%) and Alhambra Investment Management LLC (0.05%). Insiders that own company stock include Thomas Sandgaard, Joshua R Disbrow, Anna Lucsok and Daniel J Moorhead.
View institutional ownership trends
.

Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zynex investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY) and Humana (HUM).

Company Calendar

Last Earnings
3/11/2025
Today
4/25/2025
Next Earnings (Estimated)
4/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Electromedical equipment
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:ZYXI
Fax
N/A
Employees
770
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.25
High Stock Price Target
$15.00
Low Stock Price Target
$5.50
Potential Upside/Downside
+325.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
16.07
Forward P/E Ratio
12.05
P/E Growth
N/A
Net Income
$9.73 million
Pretax Margin
3.48%

Debt

Sales & Book Value

Annual Sales
$192.35 million
Cash Flow
$0.13 per share
Price / Cash Flow
18.01
Book Value
$1.36 per share
Price / Book
1.77

Miscellaneous

Free Float
15,245,000
Market Cap
$72.85 million
Optionable
Optionable
Beta
1.09
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ZYXI) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners